Close menu




April 9th, 2020 | 10:32 CEST

Commerzbank, Royal Dutch Shell, Wirecard - Opportunities and Potentials

  • Investments
Photo credits: pixabay.com

Price developments on stock markets around the world have led to enormous losses for investors in recent weeks. Particularly hard hit were investors who worked leveraged with credits and had to sell their positions in connection with falling prices. An escalating situation due to the Corona Pandemic, accelerated by imbalances - a nightmare. The development of measures to curb the spread has serious social and economic consequences. There was a sell-off in all asset classes. A lot of collateral damage, but at the same time an opportunity for building a position.

time to read: 1 minutes | Author: Mario Hose
ISIN: DE000CBK1001 , GB00B03MLX29 , DE0007472060

Table of contents:


    In purchasing is the profit

    The oil price will be in the spotlight today as a video conference of OPEC+ member countries is expected to result in a cut in production. Due to the drop in demand for the black gold as a result of the Corona Crisis, the price has fallen. The oversupply must be reduced in a concerted manner by the producers in order to increase the profit margins per barrel.

    Companies like Royal Dutch Shell and Saturn Oil & Gas are therefore in the focus of investors. The CEO of Saturn Oil & Gas, John Jeffrey, recently announced that he will be prioritizing ESG criteria from now on. The appointment of dynaCERT CEO Jim Payne as a new board member supports this step. As a CleanTech company, dynaCERT has developed a hydrogen technology that will be used in the oil industry in the future.

    Growth market fertility treatment

    In a recent interview, Alison Coutts, Executive Chairman of Memphasys, announced that the company expects to begin distributing FELIX in the second half of this year. The FELIX device helps in the separation of sperm for couples who wish to have children. In addition, the medical innovation should also be able to be used for animals in the future. The market for artificial insemination is growing because more and more couples decide to have their own child at a later age and the natural chances of a successful pregnancy then decrease significantly.

    Full video with Alison Coutts

    Investors shy away from risk

    The two financial houses Commerzbank and Wirecard have also come under enormous pressure in recent weeks. While the Wirecard shares are already trading above the level of December 2019 again, the value of the Commerbank shares is still close to the all-time low. The advantage of the payment service provider Wirecard is that, despite curfews, online transactions are processed via the company's systems. At Commerzbank, there are fears that the default risks for the bank will increase with ongoing economic restrictions in connection with the Corona Crisis.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Mario Hose

    Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

    About the author



    Related comments:

    Commented by André Will-Laudien on January 31st, 2023 | 14:50 CET

    E-mobility 2023: The Tesla hunters are coming! BYD, Lucid Motors, Tocvan Ventures. Will the Varta share now also fly?

    • Mining
    • Gold
    • Electromobility
    • Investments

    It Is hard to believe! The Tesla share is once again making a name for itself. Analysts went into the presentation of the annual figures with cautious expectations because there were many negative rumors surrounding Elon Musk's electronics company: Fewer sales? Cars on stockpile? Again, it came as no one had expected it. Elon Musk delivered and simultaneously mocked all the shorties who wanted to push his stock below USD 100 at the turn of the year. This gambit went badly wrong because Tesla was able to deliver even better figures than expected, and there was no stopping the share. With plus 70% in only 4 weeks, the Tesla share belongs to the shooting stars since the turn of the year - the short sellers must have lost their desire completely. But the variety of interesting shares is significant. Where are the opportunities for e-investors lurking?

    Read

    Commented by Nico Popp on January 31st, 2023 | 14:33 CET

    This new project changes everything: Deutsche Bank, Aspermont, Alibaba

    • Digitization
    • Innovations
    • Technology
    • Investments

    When processes go digital, great opportunities arise: automation and scaling can ensure growth and turn established business models into high-flyers. But which companies should investors actively support in their transformation? Where is there real potential for investors, and where are companies just spreading buzzwords? We highlight three stocks for you.

    Read

    Commented by André Will-Laudien on January 30th, 2023 | 09:13 CET

    Mega biotech rally 2023! Defence Therapeutics, Bayer, BioNTech, Morphosys - Where to put the money?

    • Biotechnology
    • Cancer
    • Covid19
    • Investments

    Who would have thought it? Since the beginning of the year, the stock markets have been jubilant despite difficult predictions about the economic trend in 2023. High inflation and rising interest rates are not a good breeding ground for the popular biotech stocks because they have to constantly refinance their research expenses. As the risk fee is readjusted as costs rise, investors demand higher premiums for providing money. However, some biotech stocks have taken off since the beginning of the year despite adverse conditions. What is their secret?

    Read